Correlogic finds way around FDA demands on ovarian test
This article was originally published in Clinica
Correlogic Systems is reconfiguring its deal with two major laboratories in order to avoid having to file a premarket approval application with the US FDA for its computerised test for ovarian cancer.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.